SVB Securities analyst Joseph Schwartz maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $34.00. The company’s shares closed yesterday at $41.20.
Schwartz covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Chinook Therapeutics, and Synlogic. According to TipRanks, Schwartz has an average return of -5.9% and a 41.44% success rate on recommended stocks.
Currently, the analyst consensus on Ionis Pharmaceuticals is a Moderate Buy with an average price target of $52.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $48.82 and a one-year low of $29.68. Currently, Ionis Pharmaceuticals has an average volume of 1.09M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Read More on IONS:
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- Ionis Pharmaceuticals receives FDA Fast Track designation for olezarsen
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
- Royalty, Ionis enter into royalty agreement for up to $1.1B
